Juno Therapeutics, Inc. (NASDAQ:JUNO) was the target of some unusual options trading activity on Tuesday. Stock traders bought 6,838 put options on the stock. This represents an increase of approximately 977% compared to the typical volume of 635 put options.
Several research analysts recently commented on the stock. Barclays PLC began coverage on shares of Juno Therapeutics in a research note on Wednesday, September 6th. They issued an “overweight” rating and a $55.00 price target on the stock. Wells Fargo & Company reissued an “outperform” rating and set a $54.00 target price (up previously from $35.00) on shares of Juno Therapeutics in a research report on Tuesday, September 5th. Standpoint Research reissued a “reduce” rating on shares of Juno Therapeutics in a research report on Thursday, August 31st. ValuEngine raised shares of Juno Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 29th. Finally, Raymond James Financial, Inc. raised shares of Juno Therapeutics from a “market perform” rating to an “outperform” rating and set a $45.00 price objective on the stock in a research report on Tuesday, August 29th. Three analysts have rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $34.88.
Juno Therapeutics (NASDAQ:JUNO) traded down 0.69% during trading on Friday, hitting $44.30. 3,335,682 shares of the stock traded hands. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $47.00. The firm’s 50-day moving average is $34.04 and its 200-day moving average is $27.13. The stock’s market cap is $4.65 billion.
Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.24). Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. During the same quarter last year, the firm posted ($0.64) earnings per share. Juno Therapeutics’s revenue was down 22.8% compared to the same quarter last year. On average, analysts forecast that Juno Therapeutics will post ($3.12) EPS for the current year.
In related news, Director Anthony B. Evnin purchased 9,000 shares of Juno Therapeutics stock in a transaction that occurred on Tuesday, June 20th. The shares were bought at an average price of $24.40 per share, with a total value of $219,600.00. Following the purchase, the director now directly owns 66,301 shares of the company’s stock, valued at approximately $1,617,744.40. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Douglas K. Bratton sold 8,000,000 shares of the firm’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $27.00, for a total transaction of $216,000,000.00. The disclosure for this sale can be found here. Insiders have sold 8,119,219 shares of company stock valued at $220,455,844 in the last quarter. 15.26% of the stock is owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Utah Retirement Systems increased its holdings in shares of Juno Therapeutics by 1.8% in the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock valued at $347,000 after acquiring an additional 200 shares during the last quarter. State of Wisconsin Investment Board increased its holdings in shares of Juno Therapeutics by 1.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 210 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the last quarter. Amalgamated Bank increased its holdings in shares of Juno Therapeutics by 19.0% in the 2nd quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock valued at $326,000 after acquiring an additional 1,741 shares during the last quarter. Finally, Evercore Wealth Management LLC increased its holdings in shares of Juno Therapeutics by 6.7% in the 2nd quarter. Evercore Wealth Management LLC now owns 32,062 shares of the biopharmaceutical company’s stock valued at $958,000 after acquiring an additional 2,000 shares during the last quarter. Institutional investors and hedge funds own 70.76% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was originally posted by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://baseballnewssource.com/markets/juno-therapeutics-sees-unusually-high-options-volume-juno/1565667.html.
About Juno Therapeutics
Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.
Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with our FREE daily email newsletter.